BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, Garber JE, Kauff ND, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Merajver SD, Offit K, Pal T, Reiser G, Shannon KM, Swisher E, Vinayak S, Voian NC, Weitzel JN, Wick MJ, Wiesner GL, Dwyer M, Darlow S. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. J Natl Compr Canc Netw. 2017;15:9-20. [PMID: 28040716 DOI: 10.6004/jnccn.2017.0003] [Cited by in Crossref: 279] [Cited by in F6Publishing: 214] [Article Influence: 69.8] [Reference Citation Analysis]
Number Citing Articles
1 Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol 2018;36:414-24. [PMID: 29236593 DOI: 10.1200/JCO.2017.74.1173] [Cited by in Crossref: 93] [Cited by in F6Publishing: 34] [Article Influence: 23.3] [Reference Citation Analysis]
2 Sato K, Koyasu M, Nomura S, Sato Y, Kita M, Ashihara Y, Adachi Y, Ohno S, Iwase T, Kitagawa D, Nakashima E, Yoshida R, Miki Y, Arai M. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations. Cancer Sci 2017;108:2287-94. [PMID: 28796317 DOI: 10.1111/cas.13350] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
3 Afghahi A, Kurian AW. The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition. Curr Treat Options Oncol 2017;18:27. [PMID: 28439798 DOI: 10.1007/s11864-017-0468-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
4 Liu J, Ding G, Zou K, Jiang Z, Zhang J, Lu Y, Pignata A, Venner E, Liu P, Liu Z, Wangler MF, Sun Z. Genome sequencing analysis of a family with a child displaying severe abdominal distention and recurrent hypoglycemia. Mol Genet Genomic Med 2020;8:e1130. [PMID: 31971667 DOI: 10.1002/mgg3.1130] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Ryu JS, Lee HY, Cho EH, Yoon KA, Kim MK, Joo J, Lee ES, Kang HS, Lee S, Lee DO, Lim MC, Kong SY. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer. Cancer Sci 2020;111:3912-25. [PMID: 32761968 DOI: 10.1111/cas.14600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Taylor A, Brady AF, Frayling IM, Hanson H, Tischkowitz M, Turnbull C, Side L; UK Cancer Genetics Group (UK-CGG). Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group. J Med Genet 2018;55:372-7. [PMID: 29661970 DOI: 10.1136/jmedgenet-2017-105188] [Cited by in Crossref: 46] [Cited by in F6Publishing: 32] [Article Influence: 15.3] [Reference Citation Analysis]
7 Tosur M, Brandt ML, Athanassaki ID, Rednam SP. Considerations for total thyroidectomy in an adolescent with PTEN mutation. Ther Adv Endocrinol Metab 2018;9:299-301. [PMID: 30181857 DOI: 10.1177/2042018818784517] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Bergqvist C, Servy A, Valeyrie-Allanore L, Ferkal S, Combemale P, Wolkenstein P; NF France Network. Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966. Orphanet J Rare Dis 2020;15:37. [PMID: 32014052 DOI: 10.1186/s13023-020-1310-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 22.0] [Reference Citation Analysis]
9 Kim B, Lee H, Jang J, Kim SJ, Lee ST, Cheong JW, Lyu CJ, Min YH, Choi JR. Targeted next generation sequencing can serve as an alternative to conventional tests in myeloid neoplasms. PLoS One 2019;14:e0212228. [PMID: 30840646 DOI: 10.1371/journal.pone.0212228] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
10 Esteban I, Lopez-Fernandez A, Balmaña J. A narrative overview of the patients' outcomes after multigene cancer panel testing, and a thorough evaluation of its implications for genetic counselling. Eur J Med Genet 2019;62:342-9. [PMID: 30476626 DOI: 10.1016/j.ejmg.2018.11.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Walsh T, Mandell JB, Norquist BM, Casadei S, Gulsuner S, Lee MK, King MC. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women. JAMA Oncol 2017;3:1647-53. [PMID: 28727877 DOI: 10.1001/jamaoncol.2017.1996] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 19.0] [Reference Citation Analysis]
12 Lang GT, Shi JX, Huang L, Cao AY, Zhang CH, Song CG, Zhuang ZG, Hu X, Huang W, Shao ZM. Multiple cancer susceptible genes sequencing in BRCA-negative breast cancer with high hereditary risk. Ann Transl Med 2020;8:1417. [PMID: 33313162 DOI: 10.21037/atm-20-2999] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Toh MR, Chiang JB, Chong ST, Chan SH, Ishak NDB, Courtney E, Lee WH, Syed Abdillah Al SMFB, Carson Allen J Jr, Lim KH, Davila S, Tan P, Lim WK, Tan IBH, Ngeow J. Germline Pathogenic Variants in Homologous Recombination and DNA Repair Genes in an Asian Cohort of Young-Onset Colorectal Cancer. JNCI Cancer Spectr 2018;2:pky054. [PMID: 31360874 DOI: 10.1093/jncics/pky054] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
14 Bennett I, Tourani S, Cockburn L, Reasbeck J, Grobbelaar N, Dann S, Patrikios P, Brazier J. Breast cancer screening in women at high risk of hereditary breast cancer: an Australian experience. ANZ J Surg 2021;91:685-90. [PMID: 33000553 DOI: 10.1111/ans.16320] [Reference Citation Analysis]
15 Larouche V, Akirov A, Thain E, Kim RH, Ezzat S. Co-occurrence of breast cancer and neuroendocrine tumours: New genetic insights beyond Multiple Endocrine Neoplasia syndromes. Endocrinol Diabetes Metab 2019;2:e00092. [PMID: 31592449 DOI: 10.1002/edm2.92] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
16 Kemp Z, Turnbull A, Yost S, Seal S, Mahamdallie S, Poyastro-Pearson E, Warren-Perry M, Eccleston A, Tan MM, Teo SH, Turner N, Strydom A, George A, Rahman N. Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer. JAMA Netw Open 2019;2:e194428. [PMID: 31125106 DOI: 10.1001/jamanetworkopen.2019.4428] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
17 Abou Alaiwi S, Nassar AH, Adib E, Groha SM, Akl EW, McGregor BA, Esplin ED, Yang S, Hatchell K, Fusaro V, Nielsen S, Kwiatkowski DJ, Sonpavde GP, Pomerantz M, Garber JE, Freedman ML, Rana HQ, Gusev A, Choueiri TK. Trans-ethnic variation in germline variants of patients with renal cell carcinoma. Cell Rep 2021;34:108926. [PMID: 33789101 DOI: 10.1016/j.celrep.2021.108926] [Reference Citation Analysis]
18 Passarello K, Kurian S, Villanueva V. Endometrial Cancer: An Overview of Pathophysiology, Management, and Care. Semin Oncol Nurs. 2019;35:157-165. [PMID: 30867105 DOI: 10.1016/j.soncn.2019.02.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
19 Suarez-Kelly LP, Yu L, Kline D, Schneider EB, Agnese DM, Carson WE. Increased breast cancer risk in women with neurofibromatosis type 1: a meta-analysis and systematic review of the literature. Hered Cancer Clin Pract 2019;17:12. [PMID: 30962859 DOI: 10.1186/s13053-019-0110-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
20 Del Valle J, Rofes P, Moreno-Cabrera JM, López-Dóriga A, Belhadj S, Vargas-Parra G, Teulé À, Cuesta R, Muñoz X, Campos O, Salinas M, de Cid R, Brunet J, González S, Capellá G, Pineda M, Feliubadaló L, Lázaro C. Exploring the Role of Mutations in Fanconi Anemia Genes in Hereditary Cancer Patients. Cancers (Basel) 2020;12:E829. [PMID: 32235514 DOI: 10.3390/cancers12040829] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
21 Chen B, Zhang G, Li X, Ren C, Wang Y, Li K, Mok H, Cao L, Wen L, Jia M, Li C, Guo L, Wei G, Lin J, Li Y, Zhang Y, Han-Zhang H, Liu J, Lizaso A, Liao N. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer. Aging (Albany NY) 2020;12:3140-55. [PMID: 32091409 DOI: 10.18632/aging.102783] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
22 Bernstein-Molho R, Barnes-Kedar I, Ludman MD, Reznik G, Feldman HB, Samra NN, Eilat A, Peretz T, Peretz LP, Shapira T, Magal N, Kalis ML, Yerushalmi R, Vinkler C, Liberman S, Basel-Salmon L, Shohat M, Levy-Lahad E, Friedman E, Bazak L, Goldberg Y. The yield of full BRCA1/2 genotyping in Israeli Arab high-risk breast/ovarian cancer patients. Breast Cancer Res Treat 2019;178:231-7. [PMID: 31368036 DOI: 10.1007/s10549-019-05379-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
23 Fragoso-Ontiveros V, Velázquez-Aragón JA, Nuñez-Martínez PM, de la Luz Mejía-Aguayo M, Vidal-Millán S, Pedroza-Torres A, Sánchez-Contreras Y, Ramírez-Otero MA, Muñiz-Mendoza R, Domínguez-Ortíz J, Wegman-Ostrosky T, Bargalló-Rocha JE, Gallardo-Rincón D, Reynoso-Noveron N, Arriaga-Canon C, Meneses-García A, Herrera-Montalvo LA, Alvarez-Gomez RM. Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients. PLoS One 2019;14:e0222709. [PMID: 31545835 DOI: 10.1371/journal.pone.0222709] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
24 Suszynska M, Kozlowski P. Summary of BARD1 Mutations and Precise Estimation of Breast and Ovarian Cancer Risks Associated with the Mutations. Genes (Basel) 2020;11:E798. [PMID: 32679805 DOI: 10.3390/genes11070798] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
25 Hynes J, MacMillan A, Fernandez S, Jacob K, Carter S, Predham S, Etchegary H, Dawson L. Group plus "mini" individual pre-test genetic counselling sessions for hereditary cancer shorten provider time and improve patient satisfaction. Hered Cancer Clin Pract 2020;18:3. [PMID: 32099586 DOI: 10.1186/s13053-020-0136-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
26 Oh M, Alkhushaym N, Fallatah S, Althagafi A, Aljadeed R, Alsowaida Y, Jeter J, Martin JR, Babiker HM, McBride A, Abraham I. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate 2019;79:880-95. [PMID: 30900310 DOI: 10.1002/pros.23795] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 14.5] [Reference Citation Analysis]
27 Nunziato M, Starnone F, Lombardo B, Pensabene M, Condello C, Verdesca F, Carlomagno C, De Placido S, Pastore L, Salvatore F, D'Argenio V. Fast Detection of a BRCA2 Large Genomic Duplication by Next Generation Sequencing as a Single Procedure: A Case Report. Int J Mol Sci 2017;18:E2487. [PMID: 29165356 DOI: 10.3390/ijms18112487] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
28 Manickam K, Buchanan AH, Schwartz MLB, Hallquist MLG, Williams JL, Rahm AK, Rocha H, Savatt JM, Evans AE, Butry LM, Lazzeri AL, Lindbuchler DM, Flansburg CN, Leeming R, Vogel VG, Lebo MS, Mason-Suares HM, Hoskinson DC, Abul-Husn NS, Dewey FE, Overton JD, Reid JG, Baras A, Willard HF, McCormick CZ, Krishnamurthy SB, Hartzel DN, Kost KA, Lavage DR, Sturm AC, Frisbie LR, Person TN, Metpally RP, Giovanni MA, Lowry LE, Leader JB, Ritchie MD, Carey DJ, Justice AE, Kirchner HL, Faucett WA, Williams MS, Ledbetter DH, Murray MF. Exome Sequencing-Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants. JAMA Netw Open 2018;1:e182140. [PMID: 30646163 DOI: 10.1001/jamanetworkopen.2018.2140] [Cited by in Crossref: 84] [Cited by in F6Publishing: 66] [Article Influence: 28.0] [Reference Citation Analysis]
29 Forbes C, Fayter D, de Kock S, Quek RG. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer. Cancer Manag Res 2019;11:2321-37. [PMID: 30962720 DOI: 10.2147/CMAR.S189627] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
30 Fortuno C, Pesaran T, Mester J, Dolinsky J, Yussuf A, McGoldrick K, James PA, Spurdle AB. Genotype-phenotype correlations among TP53 carriers: Literature review and analysis of probands undergoing multi-gene panel testing and single-gene testing. Cancer Genet 2020;248-249:11-7. [PMID: 32966936 DOI: 10.1016/j.cancergen.2020.09.002] [Reference Citation Analysis]
31 Nassar AH, Abou Alaiwi S, AlDubayan SH, Moore N, Mouw KW, Kwiatkowski DJ, Choueiri TK, Curran C, Berchuck JE, Harshman LC, Nuzzo PV, Chanza NM, Van Allen E, Esplin ED, Yang S, Callis T, Garber JE, Rana HQ, Sonpavde G. Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. Genet Med 2020;22:709-18. [PMID: 31844177 DOI: 10.1038/s41436-019-0720-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
32 Niell BL, Augusto B, McIntyre M, Conley CC, Gerke T, Roetzheim R, Garcia J, Vadaparampil ST. Distribution of Estimated Lifetime Breast Cancer Risk Among Women Undergoing Screening Mammography. AJR Am J Roentgenol 2021;217:48-55. [PMID: 33978450 DOI: 10.2214/AJR.20.23333] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Jeong GW, Shin W, Lee DO, Seo SS, Kang S, Park SY, Lim MC. Uptake of Family-Specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2 Mutation. Cancer Res Treat 2021;53:207-11. [PMID: 32777875 DOI: 10.4143/crt.2020.364] [Reference Citation Analysis]
34 Koczkowska M, Krawczynska N, Stukan M, Kuzniacka A, Brozek I, Sniadecki M, Debniak J, Wydra D, Biernat W, Kozlowski P, Limon J, Wasag B, Ratajska M. Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients. Cancers (Basel) 2018;10:E442. [PMID: 30441849 DOI: 10.3390/cancers10110442] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
35 Swink A, Nair A, Hoof P, Matthews A, Burden C, Johnson K, Blum JL. Barriers to the utilization of genetic testing and genetic counseling in patients with suspected hereditary breast and ovarian cancers. Proc (Bayl Univ Med Cent) 2019;32:340-4. [PMID: 31384183 DOI: 10.1080/08998280.2019.1612702] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
36 Fortuno C, James PA, Spurdle AB. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome. Hum Mutat 2018;39:1764-73. [PMID: 30240537 DOI: 10.1002/humu.23656] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
37 Tan W, Liu M, Wang L, Guo Y, Wei C, Zhang S, Luo C, Liu N. Novel immune-related genes in the tumor microenvironment with prognostic value in breast cancer. BMC Cancer 2021;21:126. [PMID: 33549054 DOI: 10.1186/s12885-021-07837-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Vande Perre P, Toledano D, Corsini C, Escriba E, Laporte M, Bertet H, Yauy K, Toledano A, Galibert V, Baudry K, Clotet L, Million E, Picot MC, Geneviève D, Pujol P. Role of the general practitioner in the care of BRCA1 and BRCA2 mutation carriers: General practitioner and patient perspectives. Mol Genet Genomic Med 2018;6:957-65. [PMID: 30308700 DOI: 10.1002/mgg3.464] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
39 Young AL, Butow PN, Vetsch J, Quinn VF, Patenaude AF, Tucker KM, Wakefield CE. Family Communication, Risk Perception and Cancer Knowledge of Young Adults from BRCA1/2 Families: a Systematic Review. J Genet Counsel 2017;26:1179-96. [DOI: 10.1007/s10897-017-0125-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
40 Sabiani L, Barrou J, Mathis J, Eisinger F, Bannier M, Lambaudie E, Houvenaeghel G. How to manage BRCA mutation carriers? Horm Mol Biol Clin Investig 2020;41. [PMID: 32459193 DOI: 10.1515/hmbci-2019-0065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
41 Nielsen SM, Eccles DM, Romero IL, Al-Mulla F, Balmaña J, Biancolella M, Bslok R, Caligo MA, Calvello M, Capone GL, Cavalli P, Chan TLC, Claes KBM, Cortesi L, Couch FJ, de la Hoya M, De Toffol S, Diez O, Domchek SM, Eeles R, Efremidis A, Fostira F, Goldgar D, Hadjisavvas A, Hansen TVO, Hirasawa A, Houdayer C, Kleiblova P, Krieger S, Lázaro C, Loizidou M, Manoukian S, Mensenkamp AR, Moghadasi S, Monteiro AN, Mori L, Morrow A, Naldi N, Nielsen HR, Olopade OI, Pachter NS, Palmero EI, Pedersen IS, Piane M, Puzzo M, Robson M, Rossing M, Sini MC, Solano A, Soukupova J, Tedaldi G, Teixeira M, Thomassen M, Tibiletti MG, Toland A, Törngren T, Vaccari E, Varesco L, Vega A, Wallis Y, Wappenschmidt B, Weitzel J, Spurdle AB, De Nicolo A, Gómez-García EB. Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group. JCO Precis Oncol 2018;2. [PMID: 31517176 DOI: 10.1200/PO.18.00091] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
42 Padamsee TJ, Wills CE, Yee LD, Paskett ED. Decision making for breast cancer prevention among women at elevated risk. Breast Cancer Res 2017;19:34. [PMID: 28340626 DOI: 10.1186/s13058-017-0826-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 7.5] [Reference Citation Analysis]
43 So MK, Jeong TD, Lim W, Moon BI, Paik NS, Kim SC, Huh J. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines. Breast Cancer 2019;26:510-9. [PMID: 30725392 DOI: 10.1007/s12282-019-00951-w] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
44 Schwark AL, Stadler ZK. Should We Lower Our Threshold for Germline Genetic Assessment in Pancreatic Adenocarcinoma? JCO Precision Oncology 2018. [DOI: 10.1200/po.17.00227] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
45 Abul-Husn NS, Kenny EE. Personalized Medicine and the Power of Electronic Health Records. Cell 2019;177:58-69. [PMID: 30901549 DOI: 10.1016/j.cell.2019.02.039] [Cited by in Crossref: 66] [Cited by in F6Publishing: 35] [Article Influence: 66.0] [Reference Citation Analysis]
46 Neben CL, Zimmer AD, Stedden W, van den Akker J, O'Connor R, Chan RC, Chen E, Tan Z, Leon A, Ji J, Topper S, Zhou AY. Multi-Gene Panel Testing of 23,179 Individuals for Hereditary Cancer Risk Identifies Pathogenic Variant Carriers Missed by Current Genetic Testing Guidelines. J Mol Diagn 2019;21:646-57. [PMID: 31201024 DOI: 10.1016/j.jmoldx.2019.03.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 19.5] [Reference Citation Analysis]
47 Baran JA, Tsai SD, Isaza A, Brodeur GM, MacFarland SP, Zelley K, Adams DM, Franco AT, Bauer AJ. The Clinical Spectrum of PTEN Hamartoma Tumor Syndrome: Exploring the Value of Thyroid Surveillance. Horm Res Paediatr 2020;93:634-42. [PMID: 33887726 DOI: 10.1159/000515731] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and Ovarian Cancer: A Comprehensive Review. Cancers (Basel) 2020;12:E3730. [PMID: 33322519 DOI: 10.3390/cancers12123730] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
49 Pilié PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol 2019;16:81-104. [PMID: 30356138 DOI: 10.1038/s41571-018-0114-z] [Cited by in Crossref: 285] [Cited by in F6Publishing: 230] [Article Influence: 142.5] [Reference Citation Analysis]
50 Szybowska M, Mete O, Weber E, Silver J, Kim RH. Neuroendocrine Neoplasms Associated with Germline Pathogenic Variants in the Homologous Recombination Pathway. Endocr Pathol 2019;30:237-45. [PMID: 30772928 DOI: 10.1007/s12022-019-9569-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
51 Fulk K, Milam MR, Li S, Yussuf A, Black MH, Chao EC, LaDuca H, Stany MP. Women with breast and uterine cancer are more likely to harbor germline mutations than women with breast or uterine cancer alone: A case for expanded gene testing. Gynecol Oncol 2019;152:612-7. [PMID: 30612783 DOI: 10.1016/j.ygyno.2018.12.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
52 Mizukami K, Iwasaki Y, Kawakami E, Hirata M, Kamatani Y, Matsuda K, Endo M, Sugano K, Yoshida T, Murakami Y, Nakagawa H, Spurdle AB, Momozawa Y. Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes. EBioMedicine 2020;60:103033. [PMID: 32980694 DOI: 10.1016/j.ebiom.2020.103033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Jung SM, Ryu JM, Park HS, Park JS, Kang E, Lee S, Lee HB, Youn HJ, Yoo TK, Kim J, Lee JE, Han SA, Kim D, Kim SW; Korean Hereditary Breast Cancer Study Group. Trends in Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy in Korean Carriers of the BRCA1/2 Mutation. J Breast Cancer 2020;23:647-55. [PMID: 33408890 DOI: 10.4048/jbc.2020.23.e61] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Poggio F, Bruzzone M, Ceppi M, Pondé NF, La Valle G, Del Mastro L, de Azambuja E, Lambertini M. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol 2018;29:1497-508. [PMID: 29873695 DOI: 10.1093/annonc/mdy127] [Cited by in Crossref: 104] [Cited by in F6Publishing: 90] [Article Influence: 52.0] [Reference Citation Analysis]
55 Becker B, Strowd RE 3rd. Phakomatoses. Dermatol Clin 2019;37:583-606. [PMID: 31466597 DOI: 10.1016/j.det.2019.05.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
56 Toland AE, Andreassen PR. DNA repair-related functional assays for the classification of BRCA1 and BRCA2 variants: a critical review and needs assessment. J Med Genet 2017;54:721-31. [PMID: 28866612 DOI: 10.1136/jmedgenet-2017-104707] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
57 Sippo DA, Burk KS, Mercaldo SF, Rutledge GM, Edmonds C, Guan Z, Hughes KS, Lehman CD. Performance of Screening Breast MRI across Women with Different Elevated Breast Cancer Risk Indications. Radiology 2019;292:51-9. [DOI: 10.1148/radiol.2019181136] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
58 Howell SJ, Hockenhull K, Salih Z, Evans DG. Increased risk of breast cancer in neurofibromatosis type 1: current insights. Breast Cancer (Dove Med Press) 2017;9:531-6. [PMID: 28860858 DOI: 10.2147/BCTT.S111397] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
59 Skrovanek E, Dunbar-Jacob J, Dunwoody C, Wesmiller S. Integrative Review of Reproductive Decision Making of Women Who Are BRCA Positive. J Obstet Gynecol Neonatal Nurs 2020;49:525-36. [PMID: 32926832 DOI: 10.1016/j.jogn.2020.07.006] [Reference Citation Analysis]
60 Young EL, Thompson BA, Neklason DW, Firpo MA, Werner T, Bell R, Berger J, Fraser A, Gammon A, Koptiuch C, Kohlmann WK, Neumayer L, Goldgar DE, Mulvihill SJ, Cannon-Albright LA, Tavtigian SV. Pancreatic cancer as a sentinel for hereditary cancer predisposition. BMC Cancer 2018;18:697. [PMID: 29945567 DOI: 10.1186/s12885-018-4573-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
61 Fortuno C, Pesaran T, Dolinsky J, Yussuf A, McGoldrick K, Goldgar D, James PA, Spurdle AB. Differences in patient ascertainment affect the use of gene-specified ACMG/AMP phenotype-related variant classification criteria: Evidence for TP53. Hum Mutat 2020;41:537-42. [PMID: 31898864 DOI: 10.1002/humu.23972] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
62 Gómez-Flores-Ramos L, Álvarez-Gómez RM, Villarreal-Garza C, Wegman-Ostrosky T, Mohar A. Breast cancer genetics in young women: What do we know? Mutat Res Rev Mutat Res 2017;774:33-45. [PMID: 29173497 DOI: 10.1016/j.mrrev.2017.08.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
63 Hu Y, Alden RS, Odegaard JI, Fairclough SR, Chen R, Heng J, Feeney N, Nagy RJ, Shah J, Ulrich B, Gutierrez M, Lanman RB, Garber JE, Paweletz CP, Oxnard GR. Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clin Cancer Res 2017;23:7351-9. [PMID: 28947568 DOI: 10.1158/1078-0432.CCR-17-1745] [Cited by in Crossref: 43] [Cited by in F6Publishing: 15] [Article Influence: 10.8] [Reference Citation Analysis]
64 Coppa A, Nicolussi A, D'Inzeo S, Capalbo C, Belardinilli F, Colicchia V, Petroni M, Zani M, Ferraro S, Rinaldi C, Buffone A, Bartolazzi A, Screpanti I, Ottini L, Giannini G. Optimizing the identification of risk-relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families. Cancer Med 2018;7:46-55. [PMID: 29271107 DOI: 10.1002/cam4.1251] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
65 Zhang J, Yuan B, Zhang H, Li H. Human epithelial ovarian cancer cells expressing CD105, CD44 and CD106 surface markers exhibit increased invasive capacity and drug resistance. Oncol Lett 2019;17:5351-60. [PMID: 31186752 DOI: 10.3892/ol.2019.10221] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
66 Graff SL, Holder JM, Sears LE, Kurbegov D. Increase in Genetic Counseling and Testing Referrals After Breast Cancer Pathway Implementation. JCO Oncology Practice 2020;16:e1481-8. [DOI: 10.1200/jop.19.00552] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
67 Yehia L, Ni Y, Sesock K, Niazi F, Fletcher B, Chen HJL, LaFramboise T, Eng C. Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations. PLoS Genet 2018;14:e1007352. [PMID: 29684080 DOI: 10.1371/journal.pgen.1007352] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
68 Borazanci E, Korn R, Liang WS, Guarnieri C, Haag S, Snyder C, Hendrickson K, Caldwell L, Von Hoff D, Jameson G. An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor. Oncologist. 2020;25:e60-e67. [PMID: 31391296 DOI: 10.1634/theoncologist.2018-0905] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
69 Chae S, Kim EK, Jang YR, Lee AS, Kim SK, Suh DH, Kim K, No JH, Kim YB, Kim SW, Kang E. Effect of risk-reducing salpingo-oophorectomy on the quality of life in Korean BRCA mutation carriers. Asian J Surg 2021;44:1056-62. [PMID: 33573923 DOI: 10.1016/j.asjsur.2021.01.007] [Reference Citation Analysis]
70 Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, Kantarjian H, Strong L, DiNardo CD. Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud 2019;5:a003210. [PMID: 30709875 DOI: 10.1101/mcs.a003210] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
71 Williams AJ, Doherty ES, Hart MH, Grider DJ. Diffuse Gastric Ganglioneuromatosis: Novel Presentation of PTEN Hamartoma Syndrome-Case Report and Review of Gastric Ganglioneuromatous Proliferations and a Novel PTEN Gene Mutation. Case Rep Med 2018;2018:4319818. [PMID: 29770149 DOI: 10.1155/2018/4319818] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
72 Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin 2019;69:280-304. [PMID: 31099893 DOI: 10.3322/caac.21559] [Cited by in Crossref: 93] [Cited by in F6Publishing: 146] [Article Influence: 46.5] [Reference Citation Analysis]
73 Fostira F, Kostantopoulou I, Apostolou P, Papamentzelopoulou MS, Papadimitriou C, Faliakou E, Christodoulou C, Boukovinas I, Razis E, Tryfonopoulos D, Barbounis V, Vagena A, Vlachos IS, Kalfakakou D, Fountzilas G, Yannoukakos D. One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene. J Med Genet 2020;57:53-61. [PMID: 31300551 DOI: 10.1136/jmedgenet-2019-106189] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
74 Al-Shurbasi N, Hirst NA, Kohlhardt S. Sentinel Node Biopsy in Ductal Carcinoma in Situ: Is it Justifiable? Cureus 2021;13:e13062. [PMID: 33680604 DOI: 10.7759/cureus.13062] [Reference Citation Analysis]
75 Yip CH, Evans DG, Agarwal G, Buccimazza I, Kwong A, Morant R, Prakash I, Song CY, Taib NA, Tausch C, Ung O, Meterissian S. Global Disparities in Breast Cancer Genetics Testing, Counselling and Management. World J Surg 2019;43:1264-70. [PMID: 30610270 DOI: 10.1007/s00268-018-04897-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
76 Caskey R, Singletary B, Ayre K, Parker C, Krontiras H, Lancaster RB. Expectations of Surveillance for Non-BRCA Gene Mutation Carriers at Increased Risk for Breast Cancer. J Surg Res 2020;256:267-71. [PMID: 32712440 DOI: 10.1016/j.jss.2020.06.029] [Reference Citation Analysis]
77 Knerr S, Bowles EJA, Leppig KA, Buist DSM, Gao H, Wernli KJ. Trends in BRCA Test Utilization in an Integrated Health System, 2005-2015. J Natl Cancer Inst 2019;111:795-802. [PMID: 30753636 DOI: 10.1093/jnci/djz008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
78 Kurian AW, Canchola AJ, Ma CS, Clarke CA, Gomez SL. Magnitude of reduction in risk of second contralateral breast cancer with bilateral mastectomy in patients with breast cancer: Data from California, 1998 through 2015. Cancer 2020;126:958-70. [PMID: 31750934 DOI: 10.1002/cncr.32618] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
79 Ricker CN, Koff RB, Qu C, Culver J, Sturgeon D, Kingham KE, Lowstuter K, Chun NM, Rowe-Teeter C, Lebensohn A, Levonian P, Partynski K, Lara-Otero K, Hong C, Petrovchich IM, Mills MA, Hartman AR, Allen B, Ladabaum U, McDonnell K, Ford JM, Gruber SB, Kurian AW, Idos GE. Patient communication of cancer genetic test results in a diverse population. Transl Behav Med 2018;8:85-94. [PMID: 29385580 DOI: 10.1093/tbm/ibx010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
80 Kupfer SS. Gaining Ground in the Genetics of Gastric Cancer. Gastroenterology 2017;152:926-8. [DOI: 10.1053/j.gastro.2017.02.026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
81 Neviere Z, De La Motte Rouge T, Floquet A, Johnson A, Berthet P, Joly F. How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors. Ther Adv Med Oncol 2020;12:1758835919897530. [PMID: 32165926 DOI: 10.1177/1758835919897530] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
82 Nelson HD, Pappas M, Cantor A, Haney E, Holmes R. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2019;322:666-85. [PMID: 31429902 DOI: 10.1001/jama.2019.8430] [Cited by in Crossref: 43] [Cited by in F6Publishing: 24] [Article Influence: 21.5] [Reference Citation Analysis]
83 Narod SA. Personalised medicine and population health: breast and ovarian cancer. Hum Genet 2018;137:769-78. [DOI: 10.1007/s00439-018-1944-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
84 Barbosa A, Pinto P, Peixoto A, Guerra J, Pinto C, Santos C, Pinheiro M, Escudeiro C, Bartosch C, Silva J, Teixeira MR. Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2. Cancers (Basel) 2020;12:E2834. [PMID: 33008098 DOI: 10.3390/cancers12102834] [Reference Citation Analysis]
85 Manor J, Lalani SR. Overgrowth Syndromes-Evaluation, Diagnosis, and Management. Front Pediatr 2020;8:574857. [PMID: 33194904 DOI: 10.3389/fped.2020.574857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Salyer C, Kobelka C, Barrie A, Weintraub MR, Powell CB. Clinical characteristics and outcomes in elderly women with BRCA1 and BRCA2 mutations. Gynecol Oncol 2019;154:374-8. [PMID: 31160070 DOI: 10.1016/j.ygyno.2019.05.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
87 Ahlawat S, Blakeley JO, Langmead S, Belzberg AJ, Fayad LM. Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. Skeletal Radiol 2020;49:199-219. [DOI: 10.1007/s00256-019-03290-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 9.5] [Reference Citation Analysis]
88 Allen CG, Roberts M, Guan Y. Exploring Predictors of Genetic Counseling and Testing for Hereditary Breast and Ovarian Cancer: Findings from the 2015 U.S. National Health Interview Survey. J Pers Med 2019;9:E26. [PMID: 31083288 DOI: 10.3390/jpm9020026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
89 Barcenas CH, Shafaee MN, Sinha AK, Raghavendra A, Saigal B, Murthy RK, Woodson AH, Arun B. Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer. J Natl Compr Canc Netw 2018;16:518-24. [PMID: 29752326 DOI: 10.6004/jnccn.2018.7002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
90 Brioude F, Toutain A, Giabicani E, Cottereau E, Cormier-Daire V, Netchine I. Overgrowth syndromes - clinical and molecular aspects and tumour risk. Nat Rev Endocrinol 2019;15:299-311. [PMID: 30842651 DOI: 10.1038/s41574-019-0180-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
91 Kim S, Aceti M, Baroutsou V, Bürki N, Caiata-Zufferey M, Cattaneo M, Chappuis PO, Ciorba FM, Graffeo-Galbiati R, Heinzelmann-Schwarz V, Jeong J, Jung MM, Kim SW, Kim J, Lim MC, Ming C, Monnerat C, Park HS, Park SH, Pedrazzani CA, Rabaglio M, Ryu JM, Saccilotto R, Wieser S, Zürrer-Härdi U, Katapodi MC. Using a Tailored Digital Health Intervention for Family Communication and Cascade Genetic Testing in Swiss and Korean Families With Hereditary Breast and Ovarian Cancer: Protocol for the DIALOGUE Study. JMIR Res Protoc 2021;10:e26264. [PMID: 34114954 DOI: 10.2196/26264] [Reference Citation Analysis]
92 Peterson EB, Chou WS, Gaysynsky A, Krakow M, Elrick A, Khoury MJ, Kaphingst KA. Communication of cancer-related genetic and genomic information: A landscape analysis of reviews. Transl Behav Med 2018;8:59-70. [PMID: 29385592 DOI: 10.1093/tbm/ibx063] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
93 Mendivil AA, Tung PK, Bohart R, Bechtol K, Goldstein BH. Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation. Gynecol Oncol Rep 2018;26:41-4. [PMID: 30246138 DOI: 10.1016/j.gore.2018.09.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
94 Lopez-Perolio I, Leman R, Behar R, Lattimore V, Pearson JF, Castéra L, Martins A, Vaur D, Goardon N, Davy G, Garre P, García-Barberán V, Llovet P, Pérez-Segura P, Díaz-Rubio E, Caldés T, Hruska KS, Hsuan V, Wu S, Pesaran T, Karam R, Vallon-Christersson J, Borg A, Valenzuela-Palomo A, Velasco EA, Southey M, Vreeswijk MPG, Devilee P, Kvist A, Spurdle AB, Walker LC, Krieger S, de la Hoya M; kConFab Investigators. Alternative splicing and ACMG-AMP-2015-based classification of PALB2 genetic variants: an ENIGMA report. J Med Genet 2019;56:453-60. [PMID: 30890586 DOI: 10.1136/jmedgenet-2018-105834] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
95 Coury SA, Schneider KA, Schienda J, Tan W. Recognizing and Managing Children with a Pediatric Cancer Predisposition Syndrome: A Guide for the Pediatrician. Pediatr Ann 2018;47. [DOI: 10.3928/19382359-20180424-02] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
96 Jones MR, Kamara D, Karlan BY, Pharoah PD, Gayther SA. Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction. Gynecologic Oncology 2017;147:705-13. [DOI: 10.1016/j.ygyno.2017.10.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
97 Esposito MV, Minopoli G, Esposito L, D'Argenio V, Di Maggio F, Sasso E, D'Aiuto M, Zambrano N, Salvatore F. A Functional Analysis of the Unclassified Pro2767Ser BRCA2 Variant Reveals Its Potential Pathogenicity that Acts by Hampering DNA Binding and Homology-Mediated DNA Repair. Cancers (Basel) 2019;11:E1454. [PMID: 31569370 DOI: 10.3390/cancers11101454] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
98 Shin W, Jeong G, Son Y, Seo SS, Kang S, Park SY, Lim MC. The Knowledge and Attitude of Patients Diagnosed with Epithelial Ovarian Cancer towards Genetic Testing. Int J Environ Res Public Health 2021;18:2312. [PMID: 33652933 DOI: 10.3390/ijerph18052312] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Landry JP, Schertz KL, Chiang YJ, Bhalla AD, Yi M, Keung EZ, Scally CP, Feig BW, Hunt KK, Roland CL, Guadagnolo A, Bishop AJ, Lazar AJ, Slopis JM, McCutcheon IE, Torres KE. Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020. JAMA Netw Open 2021;4:e210945. [PMID: 33734413 DOI: 10.1001/jamanetworkopen.2021.0945] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
100 Nebgen DR, Hurteau J, Holman LL, Bradford A, Munsell MF, Soletsky BR, Sun CC, Chisholm GB, Lu KH. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations. Gynecologic Oncology 2018;150:79-84. [DOI: 10.1016/j.ygyno.2018.04.564] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 9.7] [Reference Citation Analysis]
101 Bernstein-molho R, Singer A, Laitman Y, Netzer I, Zalmanoviz S, Friedman E. Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms. Breast Cancer Res Treat 2019;176:165-70. [DOI: 10.1007/s10549-019-05228-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
102 Stasenko M, Fillipova O, Tew WP. Fallopian Tube Carcinoma. J Oncol Pract 2019;15:375-82. [PMID: 31283415 DOI: 10.1200/JOP.18.00662] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
103 Park CS, Park HY, Jung JH, Kim WW, Chae YS, Lee SJ, Park JY, Park JY, Lee J. Comparison of clinical features and oncologic outcomes between familial non-hereditary and hereditary breast cancer in Korean female patients. Asian J Surg 2020;43:996-1001. [PMID: 31924417 DOI: 10.1016/j.asjsur.2019.12.001] [Reference Citation Analysis]
104 Apostolou P, Fostira F, Kouroussis C, Kalfakakou D, Delimitsou A, Agelaki S, Androulakis N, Christodoulou C, Kalbakis K, Kalykaki A, Sanidas E, Papadimitriou C, Vamvakas L, Georgoulias V, Mavroudis D, Yannoukakos D, Konstantopoulou I, Saloustros E. BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects. Int J Cancer 2020;147:1334-42. [PMID: 32022259 DOI: 10.1002/ijc.32903] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
105 Mester JL, Jackson SA, Postula K, Stettner A, Solomon S, Bissonnette J, Murphy PD, Klein RT, Hruska KS. Apparently Heterozygous TP53 Pathogenic Variants May Be Blood Limited in Patients Undergoing Hereditary Cancer Panel Testing. The Journal of Molecular Diagnostics 2020;22:396-404. [DOI: 10.1016/j.jmoldx.2019.12.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
106 Sa'at H, Lee YK, Yoon SY, Wong SW, Woo YL, Barlow-Stewart K, Mohd Taib NA. The needs of Southeast Asian BRCA mutation carriers considering risk-reducing salpingo-oophorectomy: a qualitative study. Fam Cancer 2021. [PMID: 33604745 DOI: 10.1007/s10689-021-00232-6] [Reference Citation Analysis]
107 Abul-Husn NS, Soper ER, Odgis JA, Cullina S, Bobo D, Moscati A, Rodriguez JE, Loos RJF, Cho JH, Belbin GM, Suckiel SA, Kenny EE; CBIPM Genomics Team., Regeneron Genetics Center. Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank. Genome Med 2019;12:2. [PMID: 31892343 DOI: 10.1186/s13073-019-0691-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
108 Xie Y, Li G, Chen M, Guo X, Tang L, Luo X, Wang S, Yi W, Dai L, Wang J. Mutation screening of 10 cancer susceptibility genes in unselected breast cancer patients. Clin Genet 2018;93:41-51. [PMID: 28580595 DOI: 10.1111/cge.13063] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
109 Gordhandas S, Norquist BM, Pennington KP, Yung RL, Laya MB, Swisher EM. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits. Gynecologic Oncology 2019;153:192-200. [DOI: 10.1016/j.ygyno.2018.12.014] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 16.5] [Reference Citation Analysis]
110 Jonker LA, Lebbink CA, Jongmans MCJ, Nievelstein RAJ, Merks JHM, Nieveen van Dijkum EJM, Links TP, Hoogerbrugge N, van Trotsenburg ASP, van Santen HM. Recommendations on Surveillance for Differentiated Thyroid Carcinoma in Children with PTEN Hamartoma Tumor Syndrome. Eur Thyroid J 2020;9:234-42. [PMID: 33088791 DOI: 10.1159/000508872] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
111 Anceschi U, Tuderti G, Lugnani F, Biava PM, Malossini G, Luciani L, Cai T, Marsiliani D, Filianoti A, Mattevi D, Costantini M, Misuraca L, Simone G. Novel Diagnostic Biomarkers of Prostate Cancer: An Update. Curr Med Chem 2019;26:1045-58. [PMID: 30215331 DOI: 10.2174/0929867325666180914115416] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
112 Santana Dos Santos E, Lallemand F, Petitalot A, Caputo SM, Rouleau E. HRness in Breast and Ovarian Cancers. Int J Mol Sci 2020;21:E3850. [PMID: 32481735 DOI: 10.3390/ijms21113850] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
113 Evans DGR, Kallionpää RA, Clementi M, Trevisson E, Mautner VF, Howell SJ, Lewis L, Zehou O, Peltonen S, Brunello A, Harkness EF, Wolkenstein P, Peltonen J. Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study. Genet Med 2020;22:398-406. [PMID: 31495828 DOI: 10.1038/s41436-019-0651-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
114 Rudaitis V, Mikliusas V, Januska G, Jukna P, Mickys U, Janavicius R. The incidence of occult ovarian neoplasia and cancer in BRCA1/2 mutation carriers after the bilateral prophylactic salpingo-oophorectomy (PBSO): A single-center prospective study. Eur J Obstet Gynecol Reprod Biol 2020;247:26-31. [PMID: 32059136 DOI: 10.1016/j.ejogrb.2020.01.040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Crook A, Kwa R, Ephraums S, Wilding M, Thiyagarajan L, Fleming J, Moore K, Berman Y. The psychological impact and experience of breast cancer screening in young women with an increased risk of breast cancer due to neurofibromatosis type 1. Fam Cancer 2021. [PMID: 33963463 DOI: 10.1007/s10689-021-00259-9] [Reference Citation Analysis]
116 Kim HK, Lee EJ, Lee YJ, Kim J, Kim Y, Kim K, Lee SW, Chang S, Lee YJ, Lee JW, Lee W, Chun S, Son BH, Jung KH, Kim YM, Min WK, Ahn SH. Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer. J Hum Genet 2020;65:209-20. [PMID: 31907386 DOI: 10.1038/s10038-019-0713-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
117 Castillo-Guardiola V, Sarabia-Meseguer MD, Marín-Vera M, Sánchez-Bermúdez AI, Alonso-Romero JL, Noguera-Velasco JA, Ruiz-Espejo F. New insights into the performance of multigene panel testing: Two novel nonsense variants in BRIP1 and TP53 in a young woman with breast cancer. Cancer Genet 2018;228-229:1-4. [PMID: 30553462 DOI: 10.1016/j.cancergen.2018.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
118 Conley CC, Castro-Figueroa EM, Moreno L, Dutil J, García JD, Burgos C, Ricker C, Kim J, Graves KD, Ashing KT, Quinn GP, Soliman H, Vadaparampil ST. A pilot randomized trial of an educational intervention to increase genetic counseling and genetic testing among Latina breast cancer survivors. J Genet Couns 2021;30:394-405. [PMID: 32936981 DOI: 10.1002/jgc4.1324] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
119 Boitano TKL, Barrington DA, Batra S, McGwin G Jr, Turner TB, Farmer MB, Brown AM, Straughn MJ Jr, Leath CA 3rd. Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic. Gynecol Oncol 2019;154:379-82. [PMID: 31196574 DOI: 10.1016/j.ygyno.2019.05.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
120 Singhal D, Hahn CN, Feurstein S, Wee LYA, Moma L, Kutyna MM, Chhetri R, Eshraghi L, Schreiber AW, Feng J, Wang PP, Babic M, Parker WT, Gao S, Moore S, Das S, Thomas D, Pattnaik S, Brown AL, D'Andrea RJ, Poplawski NK, Thomas D, Scott HS, Godley LA, Hiwase DK. Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia 2021. [PMID: 33850299 DOI: 10.1038/s41375-021-01246-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
121 Katz SJ, Bondarenko I, Ward KC, Hamilton AS, Morrow M, Kurian AW, Hofer TP. Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer. JAMA Surg 2018;153:909-16. [PMID: 29971344 DOI: 10.1001/jamasurg.2018.2001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
122 Greenberg S, Slager S, Neil BO, Cooney K, Maughan B, Stopa N, Venne V, Zickmund S, Colonna S. What men want: Qualitative analysis of what men with prostate cancer (PCa) want to learn regarding genetic referral, counseling, and testing. Prostate 2020;80:441-50. [PMID: 32027768 DOI: 10.1002/pros.23959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
123 Liu Z, Wang Y, Shan F, Ying X, Zhang Y, Li S, Jia Y, Li Z, Ji J. 5-Fu-Based Doublet Regimen in Patients Receiving Perioperative or Postoperative Chemotherapy for Locally Advanced Gastric Cancer: When to Start and How Long Should the Regimen Last? Cancer Manag Res 2021;13:147-61. [PMID: 33469359 DOI: 10.2147/CMAR.S285361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Samadder NJ, Giridhar KV, Baffy N, Riegert-Johnson D, Couch FJ. Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1: Breast-Ovarian Cancer Syndromes. Mayo Clin Proc 2019;94:1084-98. [PMID: 31171119 DOI: 10.1016/j.mayocp.2019.02.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
125 Hao J, Hassen D, Manickam K, Murray MF, Hartzel DN, Hu Y, Liu K, Rahm AK, Williams MS, Lazzeri A, Buchanan A, Sturm A, Snyder SR. Healthcare Utilization and Costs after Receiving a Positive BRCA1/2 Result from a Genomic Screening Program. J Pers Med 2020;10:E7. [PMID: 32028596 DOI: 10.3390/jpm10010007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
126 Katz SJ, Ward KC, Hamilton AS, Mcleod MC, Wallner LP, Morrow M, Jagsi R, Hawley ST, Kurian AW. Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer. J Clin Oncol 2018;36:1218-24. [PMID: 29528794 DOI: 10.1200/JCO.2017.76.2369] [Cited by in Crossref: 36] [Cited by in F6Publishing: 18] [Article Influence: 12.0] [Reference Citation Analysis]
127 Sailer V, Eng KW, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E, Cyrta J, Rao R, Sahota S, Pauli C, Beg S, Motanagh S, Kossai M, Fontunge J, Puca L, Rennert H, Zhaoying Xiang J, Greco N, Kim R, MacDonald TY, McNary T, Blattner-Johnson M, Schiffman MH, Faltas BM, Greenfield JP, Rickman D, Andreopoulou E, Holcomb K, Vahdat LT, Scherr DS, van Besien K, Barbieri CE, Robinson BD, Fine HA, Ocean AJ, Molina A, Shah MA, Nanus DM, Pan Q, Demichelis F, Tagawa ST, Song W, Mosquera JM, Sboner A, Rubin MA, Elemento O, Beltran H. Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO Precis Oncol 2019;3. [PMID: 31592503 DOI: 10.1200/PO.19.00047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
128 Hann KEJ, Fraser L, Side L, Gessler S, Waller J, Sanderson SC, Freeman M, Jacobs I, Lanceley A; PROMISE study team. Health care professionals' attitudes towards population-based genetic testing and risk-stratification for ovarian cancer: a cross-sectional survey. BMC Womens Health 2017;17:132. [PMID: 29246147 DOI: 10.1186/s12905-017-0488-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
129 Fulton AJ, Lamarca A, Nuttall C, McCallum L, Pihlak R, O'Reilly D, Lalloo F, McNamara MG, Hubner RA, Clancy T, Valle JW. Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice. World J Gastrointest Oncol 2019;11:102-16. [PMID: 30788038 DOI: 10.4251/wjgo.v11.i2.102] [Reference Citation Analysis]
130 Heald B, Hampel H, Church J, Dudley B, Hall MJ, Mork ME, Singh A, Stoffel E, Stoll J, You YN, Yurgelun MB, Kupfer SS; Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position statement on multigene panel testing for patients with colorectal cancer and/or polyposis. Fam Cancer 2020;19:223-39. [PMID: 32172433 DOI: 10.1007/s10689-020-00170-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
131 Bernstein-molho R, Friedman E, Kedar I, Laitman Y, Allweis TM, Gal-yam EN, Feldman HB, Grinshpun A, Halpern N, Hartmajer S, Kadouri L, Katz LH, Kaufman B, Laish I, Levanon K, Philipsborn SL, Ludman M, Moran G, Peretz T, Reinstein E, Levi GR, Safra T, Shkedi S, Vinkler C, Levy Z, Goldberg Y. Diagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variants. Breast Cancer Res Treat 2020;181:445-53. [DOI: 10.1007/s10549-020-05633-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Gonzalez BD, Hoogland AI, Kasting ML, Cragun D, Kim J, Ashing K, Holt CL, Hughes Halbert C, Pal T, Vadaparampil ST. Psychosocial impact of BRCA testing in young Black breast cancer survivors. Psychooncology 2018;27:2778-85. [PMID: 30207419 DOI: 10.1002/pon.4887] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
133 Cowan ML, Vandenbussche CJ. Cancer of unknown primary: Ancillary testing of cytologic and small biopsy specimens in the era of targeted therapy. Cancer Cytopathology 2018;126:724-37. [DOI: 10.1002/cncy.22014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
134 Jacobson M, Bernardini M, Sobel ML, Kim RH, Mccuaig J, Allen L. No. 366-Gynaecologic Management of Hereditary Breast and Ovarian Cancer. Journal of Obstetrics and Gynaecology Canada 2018;40:1497-510. [DOI: 10.1016/j.jogc.2018.05.046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
135 Maimaitiaili A, Wu D, Liu Z, Liu H, Muyiduli X, Fan Z. Analysis of factors related to non-sentinel lymph node metastasis in 296 sentinel lymph node-positive Chinese breast cancer patients. Cancer Biol Med 2018;15:282-9. [PMID: 30197795 DOI: 10.20892/j.issn.2095-3941.2018.0023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
136 Bradbury AR, Patrick-Miller L, Egleston BL, Maxwell KN, DiGiovanni L, Brower J, Fetzer D, Bennett Gaieski J, Brandt A, McKenna D, Long J, Powers J, Stopfer JE, Nathanson KL, Domchek SM. Returning Individual Genetic Research Results to Research Participants: Uptake and Outcomes Among Patients With Breast Cancer. JCO Precis Oncol 2018;2. [PMID: 32095738 DOI: 10.1200/po.17.00250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
137 Carnevali I, Riva C, Chiaravalli AM, Sahnane N, Di Lauro E, Viel A, Rovera F, Formenti G, Ghezzi F, Sessa F, Tibiletti MG. Inherited cancer syndromes in 220 Italian ovarian cancer patients. Cancer Genet 2019;237:55-62. [PMID: 31447066 DOI: 10.1016/j.cancergen.2019.06.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Halverson CME, Wessinger BC, Clayton EW, Wiesner GL. Patients' willingness to reconsider cancer genetic testing after initially declining: Mention it again. Jrnl of Gene Coun 2019;29:18-24. [DOI: 10.1002/jgc4.1174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
139 Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R, Haak HR, Mihai R, Assie G, Terzolo M. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;G1-G46. [PMID: 30299884 DOI: 10.1530/eje-18-0608] [Cited by in Crossref: 220] [Cited by in F6Publishing: 92] [Article Influence: 73.3] [Reference Citation Analysis]
140 Chandrasekar T, Gross L, Gomella LG, Hegarty SE, Leong JY, Giri VN. Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for Men. European Urology Oncology 2020;3:291-7. [DOI: 10.1016/j.euo.2019.06.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
141 Henn J, Spier I, Adam RS, Holzapfel S, Uhlhaas S, Kayser K, Plotz G, Peters S, Aretz S. Diagnostic yield and clinical utility of a comprehensive gene panel for hereditary tumor syndromes. Hered Cancer Clin Pract 2019;17:5. [PMID: 30680046 DOI: 10.1186/s13053-018-0102-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
142 Tian P, Cheng X, Zhao Z, Zhang Y, Bao C, Wang Y, Cai S, Ma G, Huang Y. Spectrum of Pathogenic Germline Mutations in Chinese Lung Cancer Patients through Next-Generation Sequencing. Pathol Oncol Res 2020;26:109-14. [PMID: 31721094 DOI: 10.1007/s12253-019-00771-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
143 Jerzak KJ, Mancuso T, Eisen A. Ataxia-telangiectasia gene (ATM) mutation heterozygosity in breast cancer: a narrative review. Curr Oncol 2018;25:e176-80. [PMID: 29719442 DOI: 10.3747/co.25.3707] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 13.3] [Reference Citation Analysis]
144 Lhotova K, Stolarova L, Zemankova P, Vocka M, Janatova M, Borecka M, Cerna M, Jelinkova S, Kral J, Volkova Z, Urbanova M, Kleiblova P, Machackova E, Foretova L, Hazova J, Vasickova P, Lhota F, Koudova M, Cerna L, Tavandzis S, Indrakova J, Hruskova L, Kosarova M, Vrtel R, Stranecky V, Kmoch S, Zikan M, Macurek L, Kleibl Z, Soukupova J. Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer. Cancers (Basel) 2020;12:E956. [PMID: 32295079 DOI: 10.3390/cancers12040956] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
145 Shao D, Cheng S, Guo F, Zhu C, Yuan Y, Hu K, Wang Z, Meng X, Jin X, Xiong Y, Chai X, Li H, Zhang Y, Zhang H, Liu J, Ye M. Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high-risk Chinese individuals. Cancer Sci 2020;111:647-57. [PMID: 31742824 DOI: 10.1111/cas.14242] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
146 Fortuno C, Pesaran T, Dolinsky J, Yussuf A, McGoldrick K, Kho PF, James PA, Spurdle AB. p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patients. Cancer Genet 2019;235-236:21-7. [PMID: 31296311 DOI: 10.1016/j.cancergen.2019.05.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
147 Renault AL, Mebirouk N, Fuhrmann L, Bataillon G, Cavaciuti E, Le Gal D, Girard E, Popova T, La Rosa P, Beauvallet J, Eon-Marchais S, Dondon MG, d'Enghien CD, Laugé A, Chemlali W, Raynal V, Labbé M, Bièche I, Baulande S, Bay JO, Berthet P, Caron O, Buecher B, Faivre L, Fresnay M, Gauthier-Villars M, Gesta P, Janin N, Lejeune S, Maugard C, Moutton S, Venat-Bouvet L, Zattara H, Fricker JP, Gladieff L, Coupier I, Chenevix-Trench G, Hall J, Vincent-Salomon A, Stoppa-Lyonnet D, Andrieu N, Lesueur F; CoF-AT., GENESIS., kConFab. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers. Breast Cancer Res 2018;20:28. [PMID: 29665859 DOI: 10.1186/s13058-018-0951-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
148 Kurian AW, Ward KC, Hamilton AS, Deapen DM, Abrahamse P, Bondarenko I, Li Y, Hawley ST, Morrow M, Jagsi R, Katz SJ. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer. JAMA Oncol 2018;4:1066-72. [PMID: 29801090 DOI: 10.1001/jamaoncol.2018.0644] [Cited by in Crossref: 73] [Cited by in F6Publishing: 56] [Article Influence: 36.5] [Reference Citation Analysis]
149 Krontiras H, Farmer M, Whatley J. Breast Cancer Genetics and Indications for Prophylactic Mastectomy. Surg Clin North Am 2018;98:677-85. [PMID: 30005767 DOI: 10.1016/j.suc.2018.03.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
150 Greenberg S, Buys SS, Edwards SL, Espinel W, Fraser A, Gammon A, Hafen B, Herget KA, Kohlmann W, Roundy C, Sweeney C. Population prevalence of individuals meeting criteria for hereditary breast and ovarian cancer testing. Cancer Med 2019;8:6789-98. [PMID: 31531966 DOI: 10.1002/cam4.2534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
151 Gross AL, Blot WJ, Visvanathan K. BRCA1 and BRCA2 Testing in Medically Underserved Medicare Beneficiaries With Breast or Ovarian Cancer. JAMA 2018;320:597-8. [PMID: 30120466 DOI: 10.1001/jama.2018.8258] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
152 Caswell-Jin JL, Zimmer AD, Stedden W, Kingham KE, Zhou AY, Kurian AW. Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative. J Natl Cancer Inst 2019;111:95-8. [PMID: 30239769 DOI: 10.1093/jnci/djy147] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 41.0] [Reference Citation Analysis]
153 Macken WL, Tischkowitz M, Lachlan KL. PTEN Hamartoma tumor syndrome in childhood: A review of the clinical literature. Am J Med Genet C Semin Med Genet 2019;181:591-610. [PMID: 31609537 DOI: 10.1002/ajmg.c.31743] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
154 Beebe-Dimmer JL, Kapron AL, Fraser AM, Smith KR, Cooney KA. Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes. J Clin Oncol 2020;38:1807-13. [PMID: 32208047 DOI: 10.1200/JCO.19.02808] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 10.0] [Reference Citation Analysis]
155 Barnes-Kedar I, Bernstein-Molho R, Ginzach N, Hartmajer S, Shapira T, Magal N, Kalis ML, Peretz T, Shohat M, Basel-Salmon L, Friedman E, Bazak L, Goldberg Y. The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations. Breast Cancer Res Treat 2018;172:151-7. [PMID: 30014164 DOI: 10.1007/s10549-018-4887-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
156 Pilarski R. PTEN Hamartoma Tumor Syndrome: A Clinical Overview. Cancers (Basel) 2019;11:E844. [PMID: 31216739 DOI: 10.3390/cancers11060844] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 19.5] [Reference Citation Analysis]
157 Huilgol YS, Keane H, Shieh Y, Hiatt RA, Tice JA, Madlensky L, Sabacan L, Fiscalini AS, Ziv E, Acerbi I, Che M, Anton-Culver H, Borowsky AD, Hunt S, Naeim A, Parker BA, van 't Veer LJ, Esserman LJ; Athena Breast Health Network Investigators and Advocate Partners. Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry. NPJ Breast Cancer 2021;7:102. [PMID: 34344894 DOI: 10.1038/s41523-021-00306-9] [Reference Citation Analysis]
158 Isaacsson Velho P, Silberstein JL, Markowski MC, Luo J, Lotan TL, Isaacs WB, Antonarakis ES. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. Prostate 2018;78:401-7. [PMID: 29368341 DOI: 10.1002/pros.23484] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 18.0] [Reference Citation Analysis]
159 Radtke HB, Bergner AL, Goetsch AL, Mcgowan C, Panzer K, Cannon A. Genetic Counseling for Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis—Practice Resource of the National Society of Genetic Counselors. Jrnl of Gene Coun 2020;29:692-714. [DOI: 10.1002/jgc4.1303] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
160 Deng H, Chen M, Guo X, Heng J, Xu X, Peng L, Jiang H, Li G, Day JX, Li J, Shan D, Li Y, Zhou Y, Liu B, Dai L, Wang X, Wang J. Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients. Mol Genet Genomic Med 2019;7:e672. [PMID: 30972954 DOI: 10.1002/mgg3.672] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
161 St-Pierre D, Bouchard K, Gauthier L, Chiquette J, Dorval M; Centre ROSE. Perspectives of Women Considering Bilateral Prophylactic Mastectomy and their Peers towards a Telephone-Based Peer Support Intervention. J Genet Couns 2018;27:274-88. [PMID: 28916957 DOI: 10.1007/s10897-017-0148-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
162 Simoes Correa-Galendi J, Del Pilar Estevez Diz M, Stock S, Müller D. Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer. Appl Health Econ Health Policy 2021;19:97-109. [PMID: 32537695 DOI: 10.1007/s40258-020-00599-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
163 Liu J, Wang H, Zheng M, Deng L, Zhang X, Lin B. p53 and ANXA4/NF‑κB p50 complexes regulate cell proliferation, apoptosis and tumor progression in ovarian clear cell carcinoma. Int J Mol Med 2020;46:2102-14. [PMID: 33125094 DOI: 10.3892/ijmm.2020.4757] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Meiser B, Kaur R, Morrow A, Peate M, Wong WKT, McPike E, Cops E, Nichols C, Austin R, Fine M, Thrupp L, Ward R, Macrae F, Hiller JE, Trainer AH, Mitchell G; ICCon Audit Study Collaborative Group. Impact of national guidelines on use of BRCA1/2 germline testing, risk management advice given to women with pathogenic BRCA1/2 variants and uptake of advice. Hered Cancer Clin Pract 2021;19:24. [PMID: 33836815 DOI: 10.1186/s13053-021-00180-3] [Reference Citation Analysis]
165 Patel A, Iyer P, Matsuzaki S, Matsuo K, Sood AK, Fleming ND. Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer. Cancers (Basel) 2021;13:626. [PMID: 33562443 DOI: 10.3390/cancers13040626] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
166 Ahn HS, Ho JY, Yu J, Yeom J, Lee S, Hur SY, Jung Y, Kim K, Choi YJ. Plasma Protein Biomarkers Associated with Higher Ovarian Cancer Risk in BRCA1/2 Carriers. Cancers (Basel) 2021;13:2300. [PMID: 34064977 DOI: 10.3390/cancers13102300] [Reference Citation Analysis]
167 Niemeyer E, Mofid H, Zornig C, Burandt EC, Stein A, Block A, Volk AE. Case report: acute abdominal pain in a 37-year-old patient and the consequences for his family. BMC Gastroenterol 2020;20:129. [PMID: 32362280 DOI: 10.1186/s12876-020-01283-2] [Reference Citation Analysis]
168 Boddicker NJ, Hu C, Weitzel JN, Kraft P, Nathanson KL, Goldgar DE, Na J, Huang H, Gnanaolivu RD, Larson N, Yussuf A, Yao S, Vachon CM, Trentham-Dietz A, Teras L, Taylor JA, Scott CE, Sandler DP, Pesaran T, Patel AV, Palmer JR, Ong IM, Olson JE, O'Brien K, Neuhausen S, Martinez E, Ma H, Lindstrom S, Le Marchand L, Kooperberg C, Karam R, Hunter DJ, Hodge JM, Haiman C, Gaudet MM, Gao C, LaDuca H, Lacey JV, Dolinsky JS, Chao E, Carter BD, Burnside ES, Bertrand KA, Bernstein L, Auer PW, Ambrosone C, Yadav S, Hart SN, Polley EC, Domchek SM, Couch FJ. Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. J Clin Oncol 2021;:JCO2100531. [PMID: 34292776 DOI: 10.1200/JCO.21.00531] [Reference Citation Analysis]
169 Samadder NJ, Riegert-Johnson D, Boardman L, Rhodes D, Wick M, Okuno S, Kunze KL, Golafshar M, Uson PLS Jr, Mountjoy L, Ertz-Archambault N, Patel N, Rodriguez EA, Lizaola-Mayo B, Lehrer M, Thorpe CS, Yu NY, Esplin ED, Nussbaum RL, Sharp RR, Azevedo C, Klint M, Hager M, Macklin-Mantia S, Bryce AH, Bekaii-Saab TS, Sekulic A, Stewart AK. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome. JAMA Oncol 2021;7:230-7. [PMID: 33126242 DOI: 10.1001/jamaoncol.2020.6252] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 24.0] [Reference Citation Analysis]
170 Kim B, Tabori U, Hawkins C. An update on the CNS manifestations of brain tumor polyposis syndromes. Acta Neuropathol 2020;139:703-15. [PMID: 31970492 DOI: 10.1007/s00401-020-02124-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
171 Mandelker D, Ceyhan-Birsoy O. Evolving Significance of Tumor-Normal Sequencing in Cancer Care. Trends Cancer 2020;6:31-9. [PMID: 31952779 DOI: 10.1016/j.trecan.2019.11.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
172 Momozawa Y, Iwasaki Y, Hirata M, Liu X, Kamatani Y, Takahashi A, Sugano K, Yoshida T, Murakami Y, Matsuda K, Nakagawa H, Spurdle AB, Kubo M. Germline Pathogenic Variants in 7636 Japanese Patients With Prostate Cancer and 12 366 Controls. J Natl Cancer Inst 2020;112:369-76. [PMID: 31214711 DOI: 10.1093/jnci/djz124] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 23.0] [Reference Citation Analysis]
173 Cock-rada AM, Ossa Gomez CA. Leveraging International Collaborations to Advance Genomic Medicine in Colombia. Genomic Medicine in Emerging Economies. Elsevier; 2018. pp. 49-69. [DOI: 10.1016/b978-0-12-811531-2.00009-6] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
174 Murphy AE, Hussain L, Ho C, Dunki-jacobs E, Lee D, Tameron A, Huelsman K, Rice C, Wexelman BA. Preoperative Panel Testing for Hereditary Cancer Syndromes Does Not Significantly Impact Time to Surgery for Newly Diagnosed Breast Cancer Patients Compared with BRCA1/2 Testing. Ann Surg Oncol 2017;24:3055-9. [DOI: 10.1245/s10434-017-5957-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
175 Shin KH, Kim HH, Kwon BS, Suh DS, Joo JK, Kim KH. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis. Ann Lab Med 2020;40:40-7. [PMID: 31432638 DOI: 10.3343/alm.2020.40.1.40] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
176 Hines SL, Mohammad AN, Jackson J, Macklin S, Caulfield TR. Integrative data fusion for comprehensive assessment of a novel CHEK2 variant using combined genomics, imaging, and functional-structural assessments via protein informatics. Mol Omics 2019;15:59-66. [PMID: 30633282 DOI: 10.1039/c8mo00137e] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
177 Ly KI, Blakeley JO. The Diagnosis and Management of Neurofibromatosis Type 1. Med Clin North Am 2019;103:1035-54. [PMID: 31582003 DOI: 10.1016/j.mcna.2019.07.004] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 19.0] [Reference Citation Analysis]
178 Idos GE, Kurian AW, Ricker C, Sturgeon D, Culver JO, Kingham KE, Koff R, Chun NM, Rowe-Teeter C, Lebensohn AP, Levonian P, Lowstuter K, Partynski K, Hong C, Mills MA, Petrovchich I, Ma CS, Hartman AR, Allen B, Wenstrup RJ, Lancaster JM, Brown K, Kidd J, Evans B, Mukherjee B, McDonnell KJ, Ladabaum U, Ford JM, Gruber SB. Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk. JCO Precis Oncol 2019;3:PO. [PMID: 34322651 DOI: 10.1200/PO.18.00217] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
179 Wood ME, Rehman HT, Bedrosian I. Importance of family history and indications for genetic testing. Breast J 2020;26:100-4. [PMID: 31865627 DOI: 10.1111/tbj.13722] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
180 Chen J, Lin Y, Jia Y, Xu T, Wu F, Jin Y. LncRNA HAND2‐AS1 exerts anti‐oncogenic effects on ovarian cancer via restoration of BCL2L11 as a sponge of microRNA‐340‐5p. J Cell Physiol 2019;234:23421-36. [DOI: 10.1002/jcp.28911] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 12.5] [Reference Citation Analysis]
181 Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, Taylor N, Chamberlain A, Pope J, Raghallaigh HN, Evans DG, Rothwell J, Maehle L, Grindedal EM, James P, Mascarenhas L, McKinley J, Side L, Thomas T, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Jensen TD, Osther PJS, Helfand BT, Genova E, Oldenburg RA, Cybulski C, Wokolorczyk D, Ong KR, Huber C, Lam J, Taylor L, Salinas M, Feliubadaló L, Oosterwijk JC, van Zelst-Stams W, Cook J, Rosario DJ, Domchek S, Powers J, Buys S, O'Toole K, Ausems MGEM, Schmutzler RK, Rhiem K, Izatt L, Tripathi V, Teixeira MR, Cardoso M, Foulkes WD, Aprikian A, van Randeraad H, Davidson R, Longmuir M, Ruijs MWG, Helderman van den Enden ATJM, Adank M, Williams R, Andrews L, Murphy DG, Halliday D, Walker L, Liljegren A, Carlsson S, Azzabi A, Jobson I, Morton C, Shackleton K, Snape K, Hanson H, Harris M, Tischkowitz M, Taylor A, Kirk J, Susman R, Chen-Shtoyerman R, Spigelman A, Pachter N, Ahmed M, Ramon Y Cajal T, Zgajnar J, Brewer C, Gadea N, Brady AF, van Os T, Gallagher D, Johannsson O, Donaldson A, Barwell J, Nicolai N, Friedman E, Obeid E, Greenhalgh L, Murthy V, Copakova L, Saya S, McGrath J, Cooke P, Rønlund K, Richardson K, Henderson A, Teo SH, Arun B, Kast K, Dias A, Aaronson NK, Ardern-Jones A, Bangma CH, Castro E, Dearnaley D, Eccles DM, Tricker K, Eyfjord J, Falconer A, Foster C, Gronberg H, Hamdy FC, Stefansdottir V, Khoo V, Lindeman GJ, Lubinski J, Axcrona K, Mikropoulos C, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Dudderidge T, Offman J, Kote-Jarai Z, Vickers A, Lilja H, Eeles RA; IMPACT Study Collaborators. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. Eur Urol 2019;76:831-42. [PMID: 31537406 DOI: 10.1016/j.eururo.2019.08.019] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 23.5] [Reference Citation Analysis]
182 Hickey M, Moss KM, Mishra GD, Krejany EO, Domchek SM, Wark JD, Trainer A, Wild RA. What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. Gynecol Oncol 2021;162:88-96. [PMID: 33972087 DOI: 10.1016/j.ygyno.2021.04.038] [Reference Citation Analysis]
183 Baron R, Drucker K, Lagdamen L, Cannon M, Mancini C, Fischer-Cartlidge E. CE: Breast Cancer Screening: A Review of Current Guidelines. Am J Nurs 2018;118:34-41. [PMID: 29905576 DOI: 10.1097/01.NAJ.0000541435.60875.eb] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
184 Suszynska M, Ratajska M, Kozlowski P. BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases. J Ovarian Res 2020;13:50. [PMID: 32359370 DOI: 10.1186/s13048-020-00654-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
185 Fushimi A, Fukushima N, Suzuki T, Kudo R, Takeyama H. Features of Microcalcifications on Screening Mammography in Young Women. Asian Pac J Cancer Prev 2018;19:3591-6. [PMID: 30583687 DOI: 10.31557/APJCP.2018.19.12.3591] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
186 Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. CA Cancer J Clin 2018;68:284-96. [PMID: 29809280 DOI: 10.3322/caac.21456] [Cited by in Crossref: 876] [Cited by in F6Publishing: 772] [Article Influence: 292.0] [Reference Citation Analysis]
187 Omran M, Blomqvist L, Brandberg Y, Pal N, Kogner P, Ståhlbom AK, Tham E, Bajalica-Lagercrantz S. Whole-body MRI within a surveillance program for carriers with clinically actionable germline TP53 variants - the Swedish constitutional TP53 study SWEP53. Hered Cancer Clin Pract 2020;18:1. [PMID: 31956380 DOI: 10.1186/s13053-020-0133-5] [Reference Citation Analysis]
188 Compérat E, Wasinger G, Oszwald A, Kain R, Cancel-Tassin G, Cussenot O. The Genetic Complexity of Prostate Cancer. Genes (Basel) 2020;11:E1396. [PMID: 33255593 DOI: 10.3390/genes11121396] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
189 Burk KS, Edmonds CE, Mercaldo SF, Lehman CD, Sippo DA. The Effect of Prior Comparison MRI on Interpretive Performance of Screening Breast MRI. Journal of Breast Imaging 2020;2:36-42. [DOI: 10.1093/jbi/wbz076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
190 Gadducci A, Guarneri V, Peccatori FA, Ronzino G, Scandurra G, Zamagni C, Zola P, Salutari V. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. J Ovarian Res 2019;12:9. [PMID: 30691488 DOI: 10.1186/s13048-019-0484-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 16.0] [Reference Citation Analysis]
191 Chapman-Davis E, Zhou ZN, Fields JC, Frey MK, Jordan B, Sapra KJ, Chatterjee-Paer S, Carlson AD, Holcomb KM. Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center. J Gen Intern Med 2021;36:35-42. [PMID: 32720237 DOI: 10.1007/s11606-020-06064-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
192 Dashevsky BZ, Hayward JH, Woodard GA, Joe BN, Lee AY. Utility and Outcomes of Imaging Evaluation for Palpable Lumps in the Postmastectomy Patient. AJR Am J Roentgenol 2019;213:464-72. [PMID: 31039027 DOI: 10.2214/AJR.18.20550] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
193 Aitmagambetova M, Smagulova G, Bekmukhambetov Y, Zavalyonnaya O, Tulyaeva A. A clinical case of diagnosis of breast cancer in patients with family history of BRCA mutations 1. Rep Pract Oncol Radiother 2021;26:463-9. [PMID: 34277102 DOI: 10.5603/RPOR.a2021.0069] [Reference Citation Analysis]
194 Kasting ML, Conley CC, Hoogland AI, Scherr CL, Kim J, Thapa R, Reblin M, Meade CD, Lee MC, Pal T, Quinn GP, Vadaparampil ST. A randomized controlled intervention to promote readiness to genetic counseling for breast cancer survivors. Psychooncology 2019;28:980-8. [PMID: 30883986 DOI: 10.1002/pon.5059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
195 Pastorino L, Andreotti V, Dalmasso B, Vanni I, Ciccarese G, Mandalà M, Spadola G, Pizzichetta MA, Ponti G, Tibiletti MG, Sala E, Genuardi M, Chiurazzi P, Maccanti G, Manoukian S, Sestini S, Danesi R, Zampiga V, La Starza R, Stanganelli I, Ballestrero A, Mastracci L, Grillo F, Sciallero S, Cecchi F, Tanda ET, Spagnolo F, Queirolo P, Italian Melanoma Intergroup (IMI), Goldstein AM, Bruno W, Ghiorzo P. Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1. Cancers (Basel) 2020;12:E1007. [PMID: 32325837 DOI: 10.3390/cancers12041007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
196 Kohestani K, Chilov M, Carlsson SV. Prostate cancer screening-when to start and how to screen? Transl Androl Urol 2018;7:34-45. [PMID: 29594018 DOI: 10.21037/tau.2017.12.25] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
197 Peterson JF, Roden DM, Orlando LA, Ramirez AH, Mensah GA, Williams MS. Building evidence and measuring clinical outcomes for genomic medicine. Lancet 2019;394:604-10. [PMID: 31395443 DOI: 10.1016/S0140-6736(19)31278-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 12.5] [Reference Citation Analysis]
198 Kupfer SS, Gupta S, Weitzel JN, Samadder J. AGA Clinical Practice Update on Colorectal and Pancreatic Cancer Risk and Screening in BRCA1 and BRCA2 Carriers: Commentary. Gastroenterology 2020;159:760-4. [PMID: 32335146 DOI: 10.1053/j.gastro.2020.03.086] [Reference Citation Analysis]
199 Modell SM, Allen CG, Ponte A, Marcus G. Cancer genetic testing in marginalized groups during an era of evolving healthcare reform. J Cancer Policy 2021;28:100275. [PMID: 34178601 DOI: 10.1016/j.jcpo.2021.100275] [Reference Citation Analysis]
200 Lee TC, Reyna C, Shaughnessy E, Lewis JD. Screening of populations at high risk for breast cancer. J Surg Oncol 2019;120:820-30. [DOI: 10.1002/jso.25611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
201 Childers CP, Childers KK, Maggard-Gibbons M, Macinko J. National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer. J Clin Oncol 2017;35:3800-6. [PMID: 28820644 DOI: 10.1200/JCO.2017.73.6314] [Cited by in Crossref: 143] [Cited by in F6Publishing: 62] [Article Influence: 35.8] [Reference Citation Analysis]
202 Konstanta I, Fostira F, Apostolou P, Stratikos E, Kalfakakou D, Pampanos A, Kollia P, Papadimitriou C, Konstantopoulou I, Yannoukakos D. Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece. J Hum Genet 2018;63:1149-58. [PMID: 30111881 DOI: 10.1038/s10038-018-0498-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
203 Williams CD, Bullard AJ, O’leary M, Thomas R, Redding TS, Goldstein K. Racial/Ethnic Disparities in BRCA Counseling and Testing: a Narrative Review. J Racial and Ethnic Health Disparities 2019;6:570-83. [DOI: 10.1007/s40615-018-00556-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
204 Defrancesco MS, Waldman RN, Pearlstone MM, Karanik D, Bernhisel R, Logan J, Alico L, Adkins RT. Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting. Obstetrics & Gynecology 2018;132:1121-9. [DOI: 10.1097/aog.0000000000002916] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
205 Seo YK, Yang GE, Ohk TG. A Case of Cowden Syndrome with Bilateral Breast Cancer: Invasive Carcinoma of No Special Type and Pure Cribriform Carcinoma. Iran J Radiol 2020;17. [DOI: 10.5812/iranjradiol.91951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
206 Zeng C, Guo X, Wen W, Shi J, Long J, Cai Q, Shu XO, Xiang Y, Zheng W. Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women. Breast Cancer Res Treat 2020;181:465-73. [PMID: 32318955 DOI: 10.1007/s10549-020-05643-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
207 Altman AM, Hui JYC, Tuttle TM. Quality-of-life implications of risk-reducing cancer surgery. British Journal of Surgery 2018;105:e121-30. [DOI: 10.1002/bjs.10725] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
208 Temkin SM, Bergstrom J, Samimi G, Minasian L. Ovarian Cancer Prevention in High-risk Women. Clin Obstet Gynecol 2017;60:738-57. [PMID: 28957949 DOI: 10.1097/GRF.0000000000000318] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 4.3] [Reference Citation Analysis]
209 Rana HQ, Sacca R, Drogan C, Gutierrez S, Schlosnagle E, Regan MM, Speare V, LaDuca H, Dolinsky J, Garber JE, Overmoyer BA. Prevalence of germline variants in inflammatory breast cancer. Cancer 2019;125:2194-202. [PMID: 30933323 DOI: 10.1002/cncr.32062] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
210 Urbina-Jara LK, Rojas-Martinez A, Martinez-Ledesma E, Aguilar D, Villarreal-Garza C, Ortiz-Lopez R. Landscape of Germline Mutations in DNA Repair Genes for Breast Cancer in Latin America: Opportunities for PARP-Like Inhibitors and Immunotherapy. Genes (Basel) 2019;10:E786. [PMID: 31658756 DOI: 10.3390/genes10100786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
211 Cremin C, Lee MK, Hong Q, Hoeschen C, Mackenzie A, Dixon K, McCullum M, Nuk J, Kalloger S, Karasinska J, Scudamore C, Kim PTW, Donnellan F, Lam ECS, Lim HJ, Neben CL, Stedden W, Zhou AY, Schaeffer DF, Sun S, Renouf DJ, Schrader KA. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening. Cancer Med 2020;9:4004-13. [PMID: 32255556 DOI: 10.1002/cam4.2973] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
212 Boerner T, Long Roche K. Salpingectomy for the Risk Reduction of Ovarian Cancer: Is It Time for a Salpingectomy-alone Approach? J Minim Invasive Gynecol 2021;28:403-8. [PMID: 33038519 DOI: 10.1016/j.jmig.2020.09.020] [Reference Citation Analysis]
213 Tao K, Guo S, Chen R, Yang C, Jian L, Yu H, Liu S. Lysophosphatidic Acid Receptor 6 (LPAR6) Expression and Prospective Signaling Pathway Analysis in Breast Cancer. Mol Diagn Ther 2019;23:127-38. [PMID: 30694446 DOI: 10.1007/s40291-019-00384-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
214 Kurian AW, Bernhisel R, Larson K, Caswell-Jin JL, Shadyab AH, Ochs-Balcom H, Stefanick ML. Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer. JAMA 2020;323:995-7. [PMID: 32154851 DOI: 10.1001/jama.2020.0229] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]